Rapid decline of anti-SARS-CoV-2 antibodies in patients on haemodialysis: the COVID-FRIAT study.

Roberto Alcázar-ArroyoJose M PortolésPaula López-SánchezFelipe ZalameaKarina FurazÁngel MéndezLuis NietoRosa Sánchez-HernándezSoledad PizarroAlicia GarcíaMónica PereiraEduardo Gallego-ValcárcelRosario Llópez-CarratalaIgnacio Gadea-GironésRoberto MartínBlanca Mirandanull null

Published in: Clinical kidney journal (2021)

The anti-SARS-CoV-2 antibody immune response in HD patients depends on clinical presentation. The antibody titres decay earlier than previously reported for the general population. This inadequate immune response raises questions about the efficacy of future vaccines.

Keyphrases

sars cov
end stage renal disease
immune response
chronic kidney disease
ejection fraction
newly diagnosed
peritoneal dialysis
coronavirus disease
prognostic factors
respiratory syndrome coronavirus
toll like receptor
patient reported outcomes
current status